Ridgetech (RDGT) AI Stock Analysis

• Market Cap: $6.87M
• Dividend Yield: N/A
• Average Volume (3M): 62.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: -22.37%
• EPS Growth: 63.14%
• Country: US
• Employees: 939
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Distribution
• EPS (TTM): N/A
• Shares Outstanding: 5,855,009
• 10 Day Avg. Volume: 83,275
• 30 Day Avg. Volume: 62,926
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.05
• P/FCF Ratio: 9.20
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: -0.01
• Enterprise Value/Gross Profit: -0.07
• Enterprise Value/Ebitda: 0.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $1.00 ▼(-19.35% Downside)

Ridgetech's overall stock score is primarily impacted by its mixed financial performance and concerning valuation metrics. While the company has achieved profitability, revenue decline and operational inefficiencies are significant challenges. Technical analysis shows moderate strength, but the negative P/E ratio and lack of dividend yield weigh heavily on the stock's attractiveness. Continued focus on improving revenue and operational efficiency is crucial for enhancing the stock's appeal.

Ridgetech Business Overview & Revenue Model

Company Description

Ridgetech Inc operates as a holding company. The Company, through its subsidiaries, wholesales, distributes, and retails pharmaceutical and other healthcare products.

How the Company Makes Money

Ridgetech generates revenue through a diversified model that includes subscription fees for its software services, one-time sales of hardware used in precision agriculture, and consulting fees for tailored analytics solutions. Key revenue streams consist of recurring subscriptions from agribusinesses utilizing their cloud-based analytics platform, which offers continuous access to data insights and updates. Additionally, partnerships with agricultural equipment manufacturers and research institutions enhance their market reach and credibility, driving further sales through co-developed products and joint marketing initiatives.

Ridgetech Financial Statement Overview

Summary

China Jo-Jo Drugstores is facing significant financial challenges across all key areas. The income statement reflects ongoing operational difficulties with consistent losses and negative margins. The balance sheet shows financial instability with high leverage and declining equity. Cash flow issues further compound these problems, with negative operational cash flows and reliance on financing activities. Overall, the company's current financial state indicates a need for strategic adjustments to improve stability and profitability.

Income Statement

China Jo-Jo Drugstores has shown a declining trend in revenue with a negative revenue growth rate over the past three years. The company has been consistently reporting net losses, leading to negative net profit margins. The gross profit margin has remained relatively stable but is overshadowed by the persistent negative EBIT and EBITDA margins, indicating challenges in operational efficiency and profitability.

Balance Sheet

The balance sheet indicates a high level of debt relative to equity, with an increasing debt-to-equity ratio over time. Stockholders' equity has been decreasing, reflecting the ongoing net losses. The equity ratio has been decreasing, signaling reduced financial stability. Overall, the company's balance sheet shows financial strain, with high leverage and declining equity.

Cash Flow

The cash flow statement reveals negative operating cash flow, which, combined with negative free cash flow, suggests challenges in generating cash from operations. The company has also experienced a negative free cash flow growth rate, indicating deteriorating cash flow health. The financing activities have been the primary source of cash inflows, which may not be sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	147.13M	119.97M	154.54M	154.54M	154.54M	154.54M
Gross Profit	29.77M	3.84M	31.11M	31.11M	31.11M	31.11M
EBITDA	-5.06M	4.98M	1.23M	1.23M	1.23M	1.23M
Net Income	-5.59M	10.19M	-4.23M	-4.23M	-4.23M	-4.23M
Balance Sheet
Total Assets	94.19M	64.48M	95.06M	95.06M	95.06M	95.06M
Cash, Cash Equivalents and Short-Term Investments	18.00M	12.78M	20.15M	20.15M	20.15M	20.15M
Total Debt	42.17M	10.39M	43.22M	43.22M	43.22M	43.22M
Total Liabilities	74.07M	34.85M	80.76M	80.76M	80.76M	80.76M
Stockholders Equity	21.47M	29.64M	15.64M	15.64M	15.64M	15.64M
Cash Flow
Free Cash Flow	-14.94M	632.50K	-4.08M	-4.08M	-4.08M	-4.08M
Operating Cash Flow	-13.83M	1.25M	-3.16M	-3.16M	-3.16M	-3.16M
Investing Cash Flow	-1.14M	-18.14M	-2.04M	-2.04M	-2.04M	-2.04M
Financing Cash Flow	15.50M	1.51M	8.00M	8.00M	8.00M	8.00M

Ridgetech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDGT, the sentiment is Neutral. The current price of 1.24 is below the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.13, and below the 200-day MA of 1.43, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 29.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RDGT.

Ridgetech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GEG	55 Neutral	$60.07M	―	-2.28%	―	64.34%	70.95%
Sector *	50 Neutral	AU$2.60B	3.64	-58.14%	2.69%	36.37%	13.78%
RDGT	49 Neutral	$6.87M	―	-6.45%	―	-22.37%	63.14%
SNYR	47 Neutral	$33.44M	3.24	-23.21%	―	―	―
ZYXI	43 Neutral	$47.26M	24.14	-168.22%	―	-25.21%	-631.48%